Additionally, drugs specific for molecular targets, such as inhibitors of EGFR, PARP, BRAF, MEK, ALK/ROS, and HDAC, are part of a promising therapeutic approach for metastatic NSCLC and exhibited distinct effects on the RIIR (Supplementary Fig. 4). This evidence concerns the gene BRAF and non-small cell lung carcinoma.